CN104755484B - Bace抑制剂 - Google Patents

Bace抑制剂 Download PDF

Info

Publication number
CN104755484B
CN104755484B CN201380055699.5A CN201380055699A CN104755484B CN 104755484 B CN104755484 B CN 104755484B CN 201380055699 A CN201380055699 A CN 201380055699A CN 104755484 B CN104755484 B CN 104755484B
Authority
CN
China
Prior art keywords
mmol
compound
methanol
solution
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380055699.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104755484A (zh
Inventor
F·M·马丁
D·J·梅戈特
W·M·欧弗顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104755484A publication Critical patent/CN104755484A/zh
Application granted granted Critical
Publication of CN104755484B publication Critical patent/CN104755484B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380055699.5A 2012-10-26 2013-10-17 Bace抑制剂 Expired - Fee Related CN104755484B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718728P 2012-10-26 2012-10-26
US61/718,728 2012-10-26
PCT/US2013/065418 WO2014066132A1 (en) 2012-10-26 2013-10-17 Bace inhibitors

Publications (2)

Publication Number Publication Date
CN104755484A CN104755484A (zh) 2015-07-01
CN104755484B true CN104755484B (zh) 2016-02-17

Family

ID=49515508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380055699.5A Expired - Fee Related CN104755484B (zh) 2012-10-26 2013-10-17 Bace抑制剂

Country Status (17)

Country Link
US (1) US9328124B2 (enExample)
EP (1) EP2912041B1 (enExample)
JP (1) JP6243921B2 (enExample)
CN (1) CN104755484B (enExample)
CA (1) CA2886507C (enExample)
CY (1) CY1118623T1 (enExample)
DK (1) DK2912041T3 (enExample)
ES (1) ES2616835T3 (enExample)
HR (1) HRP20170025T1 (enExample)
HU (1) HUE031764T2 (enExample)
LT (1) LT2912041T (enExample)
ME (1) ME02576B (enExample)
PL (1) PL2912041T3 (enExample)
PT (1) PT2912041T (enExample)
RS (1) RS55561B1 (enExample)
SI (1) SI2912041T1 (enExample)
WO (1) WO2014066132A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014223334C1 (en) 2013-03-01 2018-10-18 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
EP2964644B1 (en) 2013-03-08 2018-12-26 Amgen, Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
TWI684452B (zh) * 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
MX381482B (es) 2014-08-08 2025-03-12 Amgen Inc Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
US10246429B2 (en) 2015-08-06 2019-04-02 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
MX388697B (es) 2016-12-15 2025-03-20 Amgen Inc Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
AU2017376441B2 (en) 2016-12-15 2021-10-14 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
MX386618B (es) 2016-12-15 2025-03-19 Amgen Inc Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.
MX387729B (es) 2016-12-15 2025-03-18 Amgen Inc Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso.
AU2017376445B2 (en) 2016-12-15 2021-09-30 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
CN106632001A (zh) * 2016-12-28 2017-05-10 山东诚汇双达药业有限公司 一种4‑(溴乙酰基)吡啶氢溴酸盐的制备方法
CN110452179A (zh) * 2019-06-25 2019-11-15 南京普锐达医药科技有限公司 一种2-氯-4-甲氧基-5-氰基嘧啶的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228163A (zh) * 2005-06-14 2008-07-23 先灵公司 天冬氨酰蛋白酶抑制剂
EP2511269A1 (en) * 2009-12-11 2012-10-17 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
AU2009239536C1 (en) * 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
TW201302763A (zh) 2011-05-24 2013-01-16 必治妥美雅史谷比公司 用於減少β-類澱粉產生之化合物
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين
GB201212871D0 (en) * 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228163A (zh) * 2005-06-14 2008-07-23 先灵公司 天冬氨酰蛋白酶抑制剂
EP2511269A1 (en) * 2009-12-11 2012-10-17 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group

Also Published As

Publication number Publication date
HRP20170025T1 (hr) 2017-03-10
CA2886507C (en) 2016-09-20
RS55561B1 (sr) 2017-05-31
LT2912041T (lt) 2017-03-10
PL2912041T3 (pl) 2017-06-30
US20150232483A1 (en) 2015-08-20
CN104755484A (zh) 2015-07-01
US9328124B2 (en) 2016-05-03
ME02576B (me) 2017-06-20
ES2616835T3 (es) 2017-06-14
WO2014066132A1 (en) 2014-05-01
SI2912041T1 (sl) 2017-02-28
PT2912041T (pt) 2017-02-13
CY1118623T1 (el) 2017-07-12
CA2886507A1 (en) 2014-05-01
JP2015535247A (ja) 2015-12-10
EP2912041A1 (en) 2015-09-02
HUE031764T2 (en) 2017-07-28
JP6243921B2 (ja) 2017-12-06
EP2912041B1 (en) 2016-12-14
DK2912041T3 (en) 2017-02-27

Similar Documents

Publication Publication Date Title
CN104755484A (zh) Bace抑制剂
CN105026404B (zh) 四氢吡咯并噻嗪化合物
TWI599358B (zh) 組合療法
TWI431004B (zh) Bace抑制劑
CN107257801B (zh) 选择性bace1抑制剂
TWI639607B (zh) Bace抑制劑
KR20010083042A (ko) 피롤로[2,3디]피리미딘 조성물 및 이의 용도
CN104185635B (zh) 四氢吡咯并噻嗪化合物
CN106459043A (zh) 萘啶二酮衍生物
CN106661053B (zh) 吡啶基-三氮杂二环类化合物
JP6777668B2 (ja) 選択的bace1阻害剤
CN106068269B (zh) 氨基噻嗪化合物
CN106661054B (zh) 作为bace抑制剂的四氢吡咯并[3,4-d][1,3]噻嗪衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160217

Termination date: 20191017